Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SangStat

Executive Summary

Company expects approvals for SangStat's thymoglobulin and cyclosporine for prevention of graft rejection in patients undergoing organ transplant "very, very soon," SangStat CEO Philippe Pouletty announced Oct. 6 at the Warburg Dillon Read analyst conference. FDA has told the company that the approvals are imminent, Pouletty said. If approved, SangStat cyclosporine (Sang-35) will be the first branded generic cyclosporine in the U.S. Novartis' Neoral (cyclosporine microemulsion) earned $1.3 bil. last year, according to SangStat estimates. In the pivotal trial for Sang-35, the drug showed 99% bioequivalence to Neoral, the company said. SangStat plans to compete with Novartis by offering a 15%-20% discount over Neoral, which can cost up to $7,000 per year
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS033016

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel